metricas
covid
Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) Predictive factors of pathological complete response after induction (ypT0N0M0) ...
Información de la revista
Vol. 100. Núm. 6.
Páginas 345-351 (junio 2022)
Visitas
464
Vol. 100. Núm. 6.
Páginas 345-351 (junio 2022)
Original article
Acceso a texto completo
Predictive factors of pathological complete response after induction (ypT0N0M0) in non-small cell lung cancer and short-term outcomes: Results of the Spanish Group of Video-assisted Thoracic Surgery (GE-VATS)
Factores predictores de respuesta completa patológica tras inducción (ypT0N0M0) en cáncer de pulmón no microcítico y resultados a corto plazo: resultados del Grupo Español de Cirugía Torácica Videoasistida (GE-VATS)
Visitas
464
María Teresa Gómez Hernándeza,
Autor para correspondencia
mtgh@usal.es

Corresponding author.
, Nuria María Novoa Valentína, Marta G Fuentes Gagoa, Raúl Embún Florb, David Gómez de Antonioc, Marcelo F Jiménez Lópeza, Spanish Group of Video-assisted Thoracic Surgery
a Servicio de Cirugía Torácica, Hospital Universitario de Salamanca, Salamanca, Spain
b Servicio de Cirugía Torácica, Hospital Universitario Miguel Servet and Hospital Clínico Universitario Lozano Blesa, Instituto de Investigación Sanitaria Aragón, Universidad de Zaragoza, Zaragoza, Spain
c Servicio de Cirugía Torácica, Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Abstract
Introduction

To analyze the predictors of pCR in NSCLC patients who underwent anatomical lung resection after induction therapy and to evaluate the postoperative results of these patients.

Methods

All patients prospectively registered in the database of the GE-VATS working group undergone anatomic lung resection by NSCLC after induction treatment and recruited between 12/20/2016 and 3/20/2018 were included in the study. The population was divided into two groups: patients who obtained a complete pathological response after induction (pCR) and patients who did not obtain a complete pathological response after induction (non-pCR). A multivariate analysis was performed using a binary logistic regression to determine the predictors of pCR and the postoperative results of patients were analyzed.

Results

Of the 241 patients analyzed, 36 patients (14.9%) achieved pCR. Predictive factors for pCR are male sex (OR: 2.814, 95% CI: 1.015−7.806), histology of squamous carcinoma (OR: 3.065, 95% CI: 1.233−7.619) or other than adenocarcinoma (OR: 5.788, 95% CI: 1.878−17.733) and induction therapy that includes radiation therapy (OR: 4.096, 95% CI: 1.785−9.401) and targeted therapies (OR: 7.625, 95% CI: 2.147−27.077). Prevalence of postoperative pulmonary complications was higher in patients treated with neoadjuvant chemo-radiotherapy (p = 0.032).

Conclusions

Male sex, histology of squamous carcinoma or other than ADC, and induction therapy that includes radiotherapy or targeted therapy are positive predictors for obtaining pCR. Induction chemo-radiotherapy is associated with a higher risk of postoperative pulmonary complications.

Keywords:
Pathological complete response
Lung cancer
VATS
Pulmonary lobectomy
Induction therapy
Neoadjuvant
Resumen
Introducción

Analizar los factores predictores de RCp en pacientes con CPNM sometidos a resección pulmonar anatómica tras terapia de inducción y evaluar los resultados postoperatorios de estos pacientes.

Métodos

Se incluyeron en el estudio todos los pacientes registrados de forma prospectiva en la base de datos del grupo de trabajo GE-VATS reclutados entre el 20/12/2016 y el 20/3/2018 sometidos a resección pulmonar anatómica por CPNM tras tratamiento de inducción. La población se dividió en dos grupos: pacientes que obtuvieron respuesta completa patológica tras inducción (RCp) y pacientes que no obtuvieron una respuesta patológica completa tras inducción (no-RCp). Se realizó un análisis multivariante mediante una regresión logística binaria para determinar los factores predictores de RCp y se analizaron los resultados postoperatorios de los pacientes.

Resultados

De los 241 pacientes analizados, 36 pacientes (14.9%) alcanzaron RCp. Los factores predictores de RCp son el sexo varón (OR: 2.814, IC 95%: 1.015−7.806), la histología de carcinoma escamoso (OR: 3.065, IC 95%: 1.233−7.619) u otra distinta de adenocarcinoma (OR: 5.788, IC 95%: 1.878−17.733) y la terapia de inducción que incluya radioterapia (OR: 4.096, IC 95%: 1.785−9.401) y terapias dirigidas (OR: 7.625, IC 95%: 2.147−27.077). La ocurrencia de complicaciones respiratorias postoperatorias fue superior en los pacientes que recibieron quimio-radioterapia de inducción (p = 0.032).

Conclusiones

El sexo varón, la histología de carcinoma escamoso o distinta de ADC y la terapia de inducción que incluya radioterapia o terapia dirigida son factores predictores positivos para la obtención de RCp. La quimio-radioterapia de inducción se asocia con un mayor riesgo de complicaciones respiratorias postoperatorias.

Palabras clave:
Respuesta completa patológica
Carcinoma pulmonar
VATS
Lobectomía pulmonar
Tratamiento de inducción
Neoadyuvancia
Texto completo
Introduction

Induction therapy followed by surgical resection and lymphadenectomy is one of the treatment options for patients diagnosed with locally advanced non-small-cell lung cancer (NSCLC)1. The goals of neoadjuvant therapy are to control and eliminate occult metastases, while reducing the size of the primary tumor and mediastinal lymph node metastases. The results of this therapeutic strategy vary considerably, from unintended disease progression to pathological complete response (pCR). When pathological complete response is obtained, defined as the absence of tumor cells in all resection samples (ypT0N0M0) after induction therapy, the long-term results are very favorable2–4. According to published data, the 5-year survival in this group of patients ranges between 53% and 67%5–11, which is similar to patients with stage Ib disease12. pCR is therefore a good prognostic factor in patients with locally advanced NSCLC treated with induction therapy and surgery.

According to different published studies, the pCR rates achieved after induction therapy vary widely, from 8% to 48%5,6,13–18. However, the studies mentioned include a small number of patients recruited for long periods in a single institution and are mainly focused on long-term results. Furthermore, significant progress has been made in recent years in the treatment of NSCLC, such as improved surgical techniques, perioperative patient management, chemotherapy, targeted therapies, and immunotherapy, which have been able to positively influence obtaining pCR and in the short- and long-term results of these patients.

Currently, however, the response rate to neoadjuvant protocols cannot be predicted in advance, and predictors of pCR have not been extensively studied to date. According to the results of Kayawake et al.18, only squamous cell carcinoma histology is positively associated with obtaining pCR.

The objectives of this present study are to identify the predictors of pCR in patients with NSCLC undergoing anatomical lung resection after induction therapy and to evaluate the postoperative results of these patients by analyzing the data of the patients registered prospectively in the multicenter database created by the Spanish Group of Video-Assisted Thoracic Surgery (GE-VATS), belonging to the Spanish Society of Thoracic Surgery (SECT). The results obtained will provide an updated view of the most relevant predictive factors for obtaining pCR in a national cohort of patients with NSCLC treated with induction therapy.

MethodsStudy population

The study included all patients who had been prospectively registered in the GE-VATS database and had undergone anatomical lung resection for NSCLC after receiving induction treatment. The patients were recruited during the period between December 20, 2016 and March 20, 2018 (15 months) by 33 Spanish thoracic surgery departments. The study was approved by the ethics committees of all participating hospitals, and specific informed consent was obtained for this study. The methodology, audit and initial results of the study have been recently published by Embún et al.19

Clinical staging of NSCLC before induction therapy was performed based on computed tomography (CT) and positron emission tomography (PET) findings, in accordance with the staging protocol proposed in the 8th edition of the TNM classification for lung cancer20. Invasive staging methods to determine lymph node status were not performed routinely in all participating hospitals, so clinical staging was based on imaging tests.

The indication for induction treatment and the type of therapy administered were determined by the multidisciplinary oncology committees of each participating hospital. Basically, induction therapy was considered in cases of suspected N2 lymph node involvement, centrally located tumors, and tumors with suspected invasion of adjacent organs to ensure free surgical margins.

The population was divided into two groups: patients who obtained pathological complete response after induction (pCR) and patients who did not obtain a pathological complete response after induction (non-pCR).

Statistical analysis

First, we analyzed the predictive factors for pCR in all patients undergoing anatomical resection after induction therapy.

The variable selected as the result was the achievement of pCR, defined as the absence of tumor cells in all resection samples (ypT0N0M0).

The baseline demographic, oncological, and surgical variables of the patients were evaluated to detect a possible association with obtaining pCR. The variables were initially assessed using a bivariate analysis. Only statistically significant variables were used as independent predictor variables in the logistic regression analysis. Data for continuous quantitative variables were expressed as mean ± standard deviation. The normal distribution of the numerical variables was previously evaluated with the Kolmogorov-Smirnov normality test. Numerical variables with normal distribution were analyzed with the Student’s t-test for independent data, while those without normal distribution were analyzed with the Mann-Whitney U test Categorical variables were expressed as frequencies and percentages and were analyzed with the chi-squared or Fisher’s exact test if the expected frequency was less than 5. The statistically significant variables in the bivariate analysis were used as independent variables in the multivariate analysis performed using binary logistic regression. Results are presented as odds ratio (OR) with 95% confidence interval (CI) and P-value.

Secondly, we analyzed the occurrence of global postoperative morbidity (reoperation, wound infection, respiratory complications, cardiovascular complications, etc.), hospital mortality, and 90-day mortality in the overall series and according to the induction treatment received using the chi-squared test.

For all analyses, a P-value <.05 was considered statistically significant. The data analysis was performed using SPSS® version 26 (IBM Corp, Chicago, Illinois, 2019).

Results

During the study period, 3085 patients were diagnosed with lung cancer, 261 (8.46%) of whom received induction treatment prior to surgery. Twenty patients were excluded due to incomplete data (7.7%). Out of the 241 patients analyzed, 36 patients (14.9%) achieved pCR.

Table 1 shows the main demographic and clinical characteristics of the patients included in each group.

Table 1.

Demographic and clinical characteristics of the population.

Variable  pCR (n = 36)  No pCR (n = 205)  P value 
Age (years)  61.98 ± 8.27  62.13 ± 9.2  0.523 
Sex, male, n (%)  30 (83.3)  132 (64.4)  0.026 
BMI  27.07 ± 4.36  26.08 ± 3.96  0.174 
Smoking, n (%)      0.580 
Never-smoker  1 (2.8)  14 (6.8)   
Ex-smoker <12 months  15 (41.7)  100 (48.8)   
Ex-smoker >12 months  10 (27.8)  45 (22)   
Active smoker  10 (27.8)  46 (22.4)   
Ischemic heart disease, n (%)  4 (11.1)  14 (6.8)  0.321 
Creatinine >2 mg/dL, n (%)  0 (0)  8 (3.9)  0.610 
VEF1ppo%  62.8 ± 14.42  66.03 ± 17.49  0.242 
DLCOppo%  60.06 ± 19.07  57.84 ± 17.31  0.494 

The results are expressed as mean ± standard deviation, except when otherwise specified. The data in bold indicate statistically significant values.

63.9% of patients received chemotherapy (CTx) as the only induction therapy, while 28.6% were treated with induction chemo-radiotherapy (CTX-RT), and 7.5% of patients targeted therapies, either associated or not with CTx.

Table 2 describes the oncological and surgical characteristics of the patients included in each group.

Table 2.

Oncological and surgical characteristics.

Variable  pCR (n = 36)  No pCR (n = 205)  P value 
Tumor size >3 cm, n (%)  12 (35.3)  93 (45.6)  0.263 
Tumor density, n (%)      0.481 
Solid  34 (94.4)  186 (90.7)   
Mixed  1 (2.8)  16 (7.8)   
Ground glass  1 (2.8)  3 (1.5)   
Central location, n (%)  25 (69.4)  111 (54.1)  0.088 
Clinical N stage (PET), n (%)      0.265 
N0  9 (25)  75 (36.6)   
N1  5 (13.9)  17 (8.3)   
N2  22 (61.1)  106 (51.7)   
N3  0 (0)  7 (3.4)   
Histology, n (%)      0.001 
ADC  9 (29)  114 (58.8)   
Squamous cell carcinoma  18 (58.1)  73 (37.6)   
Other  4 (12.9)  7 (3.6)   
Induction therapy, n (%)      0.000 
CTx  12 (33.3)  142 (69.3)   
CTX-RT  18 (50)  51 (24.9)   
Targeted therapy  6 (16.7)  12 (5.9)   
Resection type, n (%)      0.053 
Lobectomy/bilobectomy  30 (83.3)  170 (82.9)   
Segmentectomy  1 (2.8)  0 (0)   
Pneumonectomy  5 (13.9)  35 (17.1)   
Extended resection, n (%)  9 (25)  30 (14.6)  0.119 
Approach, n (%)      0.773 
Thoracotomy  27 (75)  149 (72.7)   
VATS  9 (25)  56 (27.3)   

ADC: adenocarcinoma; CTx: chemotherapy; CTX-RT: chemoradiotherapy; pCR: pathologic complete response; VATS: video-assisted thoracoscopic surgery. The data in bold indicate statistically significant values.

The predictor variables associated with obtaining pCR in the logistic regression model were male sex, histology of squamous cell carcinoma (or other than adenocarcinoma), and induction therapy that included radiotherapy or targeted therapy. The results are shown in Table 3.

Table 3.

Multivariate analysis of predictive factors associated with pCR in patients with NSCLC (expressed in odds ratio with 95% confidence interval).

Variable  OR  95% CI  P value 
Sex
Female     
Male  2.814  1.015−7.806  0.047 
Histology
ADC     
Squamous carcinoma  3.065  1.233−7.619  0.016 
Other  5.778  1.878−17.733  0.002 
Type of induction
CTx     
CTX-RT  4.096  1.785−9.401  0.001 
Targeted therapy  7.625  2.147−27.077  0.002 

ADC: adenocarcinoma; 95% CI: 95% confidence interval; OR: odds ratio; CTx: chemotherapy; CTX-RT: chemoradiotherapy. Data in bold indicate statistically significant values.

Regarding the postoperative results, 34% of the patients in the global series presented postoperative complications, and the 30-day readmission rate was 9.5%. In-hospital and 90-day mortality rates were 0.8% and 3.3%, respectively. No significant differences were detected in postoperative adverse effects depending on the induction treatment received, except in the occurrence of postoperative pulmonary complications, which were significantly higher in patients treated with induction CTX-RT (Table 4).

Table 4.

Postoperative results of the overall series and depending on the induction treatment received.

Result  Total (n = 241)  CTx (n = 154)  CTX-RT (n = 69)  Targeted therapy (n = 18)  P-value 
Total complications, n (%)  82 (34)  49 (31.8)  30 (43.5)  3 (16.7)  0.064 
Re-operation  12 (5)  5 (3.2)  6 (8.7)  1 (5.6)  0.223 
Wound infection  5 (2.1)  1 (1.3)  3 (4.3)  0 (0)  0.274 
Respiratory complications  47 (19.5)  26 (16.9)  30 (29)  1 (5.6)  0.032 
Cardiovascular complications  32 (13.3)  17 (11)  13 (18.8)  2 (11.1)  0.273 
Other complications  12 (5)  9 (5.8)  3 (4.3)  0 (0)  0.537 
Readmission, n (%)  21 (9.5)  13 (9)  6 (9.8)  2 (12.5)  0.894 
Hospital mortality, n (%)  2 (0.8)  0 (0)  2 (2.9)  0 (0.0)  0.081 
90-day mortality, n (%)  8 (3.3)  3 (1.9)  4 (5.8)  1 (5.6)  0.286 

CTx: chemotherapy; CTX-RT: chemoradiotherapy. Data in bold indicate statistically significant values.

Discussion

The most relevant findings of our study reveal that almost 15% of patients who underwent anatomical lung resection achieved pCR after induction therapy based on different regimens (CTx, CTX-RT and targeted therapy). This figure is consistent with the results of previously published studies5,6,13–18.

Second, the factors that were positively associated with obtaining pCR were male sex, histology of squamous cell carcinoma or types other than adenocarcinoma, and induction therapy that included radiotherapy or targeted therapies.

According to the results of our study, men are 2.81 times more likely to obtain pCR after induction than women. There are studies that suggest that the effect of CTx may be greater in women21, although the cause has not been clearly defined. However, a meta-analysis analyzing 11 randomized clinical trials (n = 2288) did not find clear evidence that sex was associated with a greater or lesser benefit of preoperative CTx22.

Also, similar to the report by Kayawake et al.18, we identified squamous cell carcinoma histology and other histological variants other than adenocarcinoma as positive predictive factors to achieve pCR. The probability to obtain pCR is 3 times higher in patients with squamous cell carcinoma compared to patients with adenocarcinoma. The mechanism underlying the association between squamous cell carcinoma and pCR is uncertain, but it is likely that clinicopathological and immunological differences between adenocarcinoma and other histological types may play an important role23,24. Similarly, the histological subtype has been considered a prognostic factor in patients with NSCLC, showing better survival results in patients with squamous cell histology25. However, a meta-analysis by the NSCLC Meta-analysis Collaborative Group (mentioned above)22, which analyzed the results of 14 clinical trials (n = 2359) did not identify clear evidence that the effect of preoperative CTx on survival differed depending on the histological subtype (squamous cell carcinoma versus adenocarcinoma).

The association of CTx and RT is a positive predictive factor for pCR in our analysis. The probability of obtaining pCR after preoperative treatment with CTX-RT is four times higher than with CTx alone. Among the 69 patients treated with induction CTX-RT, 18 (26.1%) achieved pCR, compared to 7.8% of the patients who received induction with CTx alone. Previous studies in which induction therapy was based on CTX-RT describe similar pCR rates, ranging from 22 %–46 %5,9–11,26. In addition, although Kayawake et al.18 did not identify RT as a positive predictive factor for obtaining pCR (OR 2.14 [0.85–5.95], P = .107), a recent study by Haque et al.27 (1750 patients treated with neoadjuvant CTX-RT and lobectomy recruited between 2004 and 2015) found that the radiation dose >54 Gy independently predicted achieving pCR.

Regarding targeted therapies, more than 30% of patients undergoing induction with this regimen achieved pCR, and the probability of obtaining pCR was almost 8 times higher in patients treated with targeted therapies like induction versus CTx alone. Therapies directed against specific molecular markers are associated with response rates that exceed 50%, with less toxicity than cytotoxic chemotherapy agents28. However, their role as induction therapy has not yet been extensively evaluated. Some case series have shown that this protocol is feasible and that surgical resection in patients treated with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors is not associated with new toxicities or higher incidence of perioperative complications29. However, long-term results from ongoing clinical trials will be needed to define the role of targeted therapies, such as induction agents.

Lastly, surgical resection after neoadjuvant therapy can be performed safely, with acceptable postoperative results. The surgical results of our series are slightly better than those published by Cerfolio et al.17, who described an overall morbidity rate of 37% and a hospital mortality rate of 2.3%, while Kayawake et al.18 reported a hospital mortality rate of 2.6%. However, our study reveals a higher prevalence of postoperative pulmonary complications in patients treated with induction CTX-RT, so the risk-benefit of this treatment strategy should be assessed individually, especially in patients with associated pulmonary pathology.

The main limitation of this study is that the data was obtained from a prospective multicenter database, whose main objective was to determine the degree of current implementation of the VATS approach for anatomical lung resections in Spain, as well as to determine the main results of this approach. Thus, we do not have certain data that could be relevant, such as the results of invasive staging, restaging after induction therapy, chemotherapy drugs used, dose of radiotherapy administered, and CTX-RT regimen used (sequential, concurrent, etc.) as neoadjuvant therapy. Likewise, we have not been able to analyze factors such as the SUV of the tumor or the degree of tumor differentiation due to the lack of complete data in the series.

Our series includes a total of 36 patients who achieved pCR after induction therapy. Considering the short duration of the recruitment period, it is one of the longest series published to date. In addition, given the prospective and multicenter nature of the study, we feel that the results reflect current clinical practice in Spain. Furthermore, we believe that this study opens the door to the creation of multidisciplinary, multi-institutional working groups and the development of joint research projects, which could resolve the main limitations of our analysis.

In conclusion, 15% of the patients we treated with induction therapy and surgery obtained pCR. In addition, we identified male sex, squamous cell carcinoma or non-ADC histology, and induction therapy (including radiation therapy or targeted therapy) as positive predictors for achieving a complete pathologic response. Lastly, we found no differences in early postoperative results between patients who achieved pCR versus those who did not.

These findings could be potentially relevant and very useful for the development of future therapeutic algorithms aimed at decision-making and treatment planning in patients with locally advanced NSCLC.

Funding

All the expenses associated with the creation and maintenance of the GEVATS database have been absorbed by Ethicon, Johnson & Johnson.

Conflict of interests

The authors have no conflict of interests to declare.

References
[1]
D.S. Ettinger, D.E. Wood, C. Aggarwal, D.L. Aisner, W. Akerley, J.R. Bauman, et al.
NCCN guidelines insights: non-small cell lung cancer, version 1.2020.
J Natl Compr Cancer Netw, 17 (2019), pp. 1464-1472
[2]
G. Marulli, E. Verderi, A. Zuin, M. Schiavon, L. Battistella, E. Perissinotto, et al.
Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
Interact Cardiovasc Thorac Surg, 19 (2014), pp. 256-262
[3]
H. Yokomise, M. Gotoh, T. Okamoto, Y. Yamamoto, S. Ishikawa, T. Nakashima, et al.
Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer.
J Thorac Cardiovasc Surg, 133 (2007), pp. 1179-1185
[4]
K. Isobe, Y. Hata, S. Sakaguchi, F. Sato, S. Takahashi, K. Sato, et al.
Pathological response and prognosis of stage III non-small cell lung cancer patients treated with induction chemoradiation.
Asia Pac J Clin Oncol, 8 (2012), pp. 260-266
[5]
A.W. Kim, M.J. Liptay, P. Bonomi, W.H. Warren, S. Basu, E.C. Farlow, et al.
Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients.
Ann Thorac Surg, 92 (2011), pp. 233-241
[6]
F. Lococo, A. Cesario, S. Margaritora, V. Dall’Armi, F. Mattei, R. Romano, et al.
Long-term results in patients with pathological complete response after induction radiochemotherapy followed by surgery for locally advanced non-small-cell lung cancer.
Eur J Cardiothorac Surg, 43 (2013), pp. e71-81
[7]
V. Steger, T. Walker, M. Mustafi, K. Lehrach, T. Kyriss, S. Veit, et al.
Surgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy: do the results justify the risk?.
Interact Cardiovasc Thorac Surg, 15 (2012), pp. 948-953
[8]
G. Friedel, W. Budach, J. Dippon, W. Spengler, S.M. Eschmann, C. Pfannenberg, et al.
Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
J Clin Oncol, 28 (2010), pp. 942-948
[9]
R.J. Cerfolio, L. Maniscalco, A.S. Bryant.
The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives.
Ann Thorac Surg, 86 (2008), pp. 912-920
[10]
C. Pöttgen, M. Stuschke, B. Graupner, D. Theegarten, T. Gauler, V. Jendrossek, et al.
Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors.
BMC Cancer, 15 (2015), pp. 363
[11]
W. Schreiner, S. Gavrychenkova, W. Dudek, R.J. Rieker, S. Lettmaier, R. Fietkau, et al.
Pathologic complete response after induction therapy-the role of surgery in stage IIIA/B locally advanced non-small cell lung cancer.
J Thorac Dis, 10 (2018), pp. 2795-2803
[12]
H. Melek, G. Çetinkaya, E. Özer, E. Yentürk, T.E. Sevinç, A.S. Bayram, et al.
Pathological complete response after neoadjuvant/induction treatment: where is its place in the lung cancer staging system?.
Eur J Cardiothorac Surg, 56 (2019), pp. 604-611
[13]
K.S. Albain, R.S. Swann, V.W. Rusch, A.T. Turrisi, F.A. Shepherd, C. Smith, et al.
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
Lancet, 374 (2009), pp. 379-386
[14]
J.R. Sonett, M.J. Krasna, M. Suntharalingam, J. Schuetz, L.A. Doyle, R. Lilenbaum, et al.
Safe pulmonary resection after chemotherapy and high-dose thoracic radiation.
Ann Thorac Surg, 68 (1999), pp. 316-320
[15]
M. Suntharalingam, R. Paulus, M.J. Edelman, M. Krasna, W. Burrows, E. Gore, et al.
Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung.
Int J Radiat Oncol Biol Phys, 84 (2012), pp. 456-463
[16]
M.A.L. Vyfhuis, W.M. Burrows, N. Bhooshan, M. Suntharalingam, J.M. Donahue, J. Feliciano, et al.
Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer.
Int J Radiat Oncol Biol Phys, 101 (2018), pp. 445-452
[17]
R.J. Cerfolio, A.S. Bryant, V.L. Jones, R.M. Cerfolio.
Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival.
Eur J Cardiothorac Surg, 35 (2009), pp. 718-723
[18]
H. Kayawake, N. Okumura, K. Yamanashi, A. Takahashi, S. Itasaka, H. Yoshioka, et al.
Non-small cell lung cancer with pathological complete response: predictive factors and surgical outcomes.
Gen Thorac Cardiovasc Surg, 67 (2019), pp. 773-781
[19]
R. Embun, I. Royo-Crespo, J.L. Recuero Díaz, S. Bolufer, S. Call, M. Congregado, et al.
Spanish Video-Assisted Thoracic Surgery Group: method, auditing, and initial results from a national prospective cohort of patients receiving anatomical lung resections.
Arch Bronconeumol, 56 (2020), pp. 718-724
[20]
P. Goldstraw, K. Chansky, J. Crowley, R. Rami-Porta, H. Asamura, W.E.E. Eberhardt, et al.
The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer.
J Thorac Oncol, 11 (2016), pp. 39-51
[21]
S. Frega, A. Dal Maso, A. Ferro, L. Bonanno, P. Conte, G. Pasello.
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): do gender and sex matter?.
Crit Rev Oncol Hematol, 138 (2019), pp. 87-103
[22]
NSCLC Meta-analysis Collaborative Group.
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.
Lancet, 383 (2014), pp. 1561-1571
[23]
T. Mizuno, T. Arimura, H. Kuroda, N. Sakakura, Y. Yatabe, Y. Sakao.
Histological type predicts mediastinal metastasis and surgical outcome in resected cN1 non-small cell lung cancer.
Gen Thorac Cardiovasc Surg, 65 (2017), pp. 519-526
[24]
X. Meng, Y. Gao, L. Yang, H. Jing, F. Teng, Z. Huang, et al.
Immune microenvironment differences between squamous and non-squamous non-small-cell lung cancer and their influence on the prognosis.
Clin Lung Cancer, 20 (2019), pp. 48-58
[25]
F. Grossi, M. Loprevite, M. Chiaramondia, P. Ceppa, C. Pera, G.B. Ratto, et al.
Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.
Eur J Cancer, 39 (2003), pp. 1242-1250
[26]
D. Shumway, K. Corbin, R. Salgia, P. Hoffman, V. Villaflor, R.M. Malik, et al.
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.
Lung Cancer, 74 (2011), pp. 446-450
[27]
W. Haque, V. Verma, E.B. Butler, B.S. Teh.
Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes.
Lung Cancer, 130 (2019), pp. 93-100
[28]
M.K. Mayekar, T.G. Bivona.
Current landscape of targeted therapy in lung cancer.
Clin Pharmacol Ther, 102 (2017), pp. 757-764
[29]
N.A. Rizvi, V. Rusch, W. Pao, J.E. Chaft, M. Ladanyi, V.A. Miller, et al.
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
Clin Cancer Res, 17 (2011), pp. 3500-3506

Please cite this article as: Gómez Hernández MT, Novoa Valentín NM, Fuentes Gago MG, Embún Flor R, Gómez de Antonio D, Jiménez López MF, et al. Factores predictores de respuesta completa patológica tras inducción (ypT0N0M0) en cáncer de pulmón no microcítico y resultados a corto plazo: resultados del Grupo Español de Cirugía Torácica Videoasistida (GE-VATS). Cir Esp. 2022;100:345–351.

Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos